학술논문
保妇康栓联合人干扰素α2b治疗高危型人乳头瘤病毒感染伴慢性宫颈炎患者的效果 / Effects of Baofukang suppository combined with human interferon α2b in treatment of patients with high-risk human papillomavirus infection and chronic cervicitis
Document Type
Academic Journal
Author
Source
中国民康医学 / Medical Journal of Chinese People's Health. 35(23):129-135
Subject
Language
Chinese
ISSN
1672-0369
Abstract
目的:观察保妇康栓联合人干扰素α2b治疗高危型人乳头瘤病毒(HPV)感染伴慢性宫颈炎患者的效果.方法:选取2022 年 1 月至 2023 年 2 月该院收治的 86 例高危型HPV感染伴慢性宫颈炎患者进行前瞻性研究,按照随机数字表法将其分为对照组和观察组各43例.对照组给予重组人干扰素α2b治疗,观察组在对照组基础上联合保妇康栓治疗,两组均持续治疗4周.比较两组临床疗效、治疗前后炎性因子[白细胞介素-6(IL-6)、肿瘤坏死因子-α(TNF-α)、超敏C反应蛋白(hs-CRP)]水平、T细胞亚群指标(CD4+、CD8+、CD4+/CD8+)水平、HPV转阴率及不良反应发生率.结果:观察组治疗总有效率为 95.35%,高于对照组的 79.07%,差异有统计学意义(P<0.05);治疗后,两组CD4+、CD4+/CD8+水平均高于治疗前,且观察组高于对照组,两组CD8+水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);两组IL-6、TNF-α及hs-CRP水平均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05);观察组HPV转阴率为 95.35%,高于对照组的 76.74%,差异有统计学意义(P<0.05);两组不良反应发生率比较,差异无统计学意义(P>0.05).结论:保妇康栓联合人干扰素α2b治疗高危型HPV感染伴慢性宫颈炎患者可提高临床疗效和HPV转阴率,减轻机体炎症反应,增强机体免疫力,效果优于单纯人干扰素α2b治疗.
Objective:To observe effects of Baofukang suppository combined with human interferon α2b in treatment of patients with high-risk human papillomavirus(HPV)infection and chronic cervicitis.Methods:A prospective study was conducted on 86 patients with high-risk HPV infection and chronic cervicitis admitted to this hospital from January 2022 to February 2023.They were divided into control group and observation group according to the random number table method,43 cases in each.The control group was treated with recombinant human interferon α2b,while the observation group was treated with Baofukang suppository on the basis of that of the control group.Both groups were treated for 4 weeks.The clinical efficacy,the levels of inflammatory factors[interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),high-sensitivity C-reactive protein(hs-CRP)],the levels of T cell subsets indexes(CD4+,CD8+,CD4+/CD8+),the HPV negative conversion rate,and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:The total effective rate of the observation group was 95.35%,which was higher than 79.07%of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of CD4+ and CD4+/CD8+ in the two groups were higher than those before the treatment,and those in the observation group were higher than those in the control group;the levels of CD8+ in the two groups were lower than those before the treatment,and that in the observation group was lower than that in the control group;and the differences were statistically significant(P<0.05).The levels of IL-6,TNF-α and hs-CRP in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The negative conversion rate of HPV in the observation group was 95.35%,which was higher than 76.74%in the control group,and the difference was statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Baofukang suppository combined with human interferon α2b in the treatment of the patients with high-risk HPV infection and chronic cervicitis can improve the clinical efficacy and the HPV negative conversion rate,reduce the body's inflammatory reactions,and enhance the body's immunity.Moreover,it is superior to single human interferon α2b treatment.
Objective:To observe effects of Baofukang suppository combined with human interferon α2b in treatment of patients with high-risk human papillomavirus(HPV)infection and chronic cervicitis.Methods:A prospective study was conducted on 86 patients with high-risk HPV infection and chronic cervicitis admitted to this hospital from January 2022 to February 2023.They were divided into control group and observation group according to the random number table method,43 cases in each.The control group was treated with recombinant human interferon α2b,while the observation group was treated with Baofukang suppository on the basis of that of the control group.Both groups were treated for 4 weeks.The clinical efficacy,the levels of inflammatory factors[interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),high-sensitivity C-reactive protein(hs-CRP)],the levels of T cell subsets indexes(CD4+,CD8+,CD4+/CD8+),the HPV negative conversion rate,and the incidence of adverse reactions were compared between the two groups before and after the treatment.Results:The total effective rate of the observation group was 95.35%,which was higher than 79.07%of the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of CD4+ and CD4+/CD8+ in the two groups were higher than those before the treatment,and those in the observation group were higher than those in the control group;the levels of CD8+ in the two groups were lower than those before the treatment,and that in the observation group was lower than that in the control group;and the differences were statistically significant(P<0.05).The levels of IL-6,TNF-α and hs-CRP in the two groups were lower than those before the treatment,those in the observation group were lower than those in the control group,and the differences were statistically significant(P<0.05).The negative conversion rate of HPV in the observation group was 95.35%,which was higher than 76.74%in the control group,and the difference was statistically significant(P<0.05).However,there was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusions:Baofukang suppository combined with human interferon α2b in the treatment of the patients with high-risk HPV infection and chronic cervicitis can improve the clinical efficacy and the HPV negative conversion rate,reduce the body's inflammatory reactions,and enhance the body's immunity.Moreover,it is superior to single human interferon α2b treatment.